RT Journal Article
SR Electronic
T1 Persistent Autoimmune Activation and Proinflammatory State in Post-COVID Syndrome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.17.21266457
DO 10.1101/2021.11.17.21266457
A1 Acosta-Ampudia, Yeny
A1 Monsalve, Diana M
A1 Rojas, Manuel
A1 Rodríguez, Yhojan
A1 Zapata, Elizabeth
A1 Ramírez-Santana, Carolina
A1 Anaya, Juan-Manuel
YR 2021
UL http://medrxiv.org/content/early/2021/11/21/2021.11.17.21266457.abstract
AB Background The immunopathological pathways enabling post-COVID syndrome (PCS) development are not entirely known. We underwent a longitudinal analysis of patients with COVID-19 who developed PCS aiming to evaluate the autoimmune and immunological status associated with this condition.Methods Thirty-three patients were included for longitudinal clinical and autoantibody analyses of whom 12 patients were assessed for cytokines and lymphocyte populations. Patients were followed during 7-11 months after acute COVID-19. Autoimmune profile and immunological status were evaluated mainly by enzyme-linked-immunosorbent assays and flow cytometry.Results Latent autoimmunity and overt autoimmunity persisted over time. A proinflammatory state was observed in patients with PCS characterized by upregulated IFN-α, TNF-α, G-CSF, IL-17A, IL-6, IL-1β, and IL-13, whereas IP-10 was decreased. In addition, PCS was characterized by increased levels of Th9, CD8+ effector T cells, naive B cells, and CD4+ effector memory T cells. Total levels of IgG S1-SARS-CoV-2 antibodies remained elevated over time.Discussion The clinical manifestations of PCS are associated with the persistence of a proinflammatory, and effector phenotype induced by SARS-CoV-2 infection. This long-term persistent immune activation may contribute to the development of latent and overt autoimmunity. Results suggest the need to evaluate the role of immunomodulation in the treatment of PCS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Universidad del Rosario grant numbers IV-FBG001, and ABN-011.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board of the CES University approved the study design.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsACAsAnti-cardiolipin antibodies.AITDAutoimmune thyroid disease.ANAsAnti-nuclear antibodies.β2GP1β2 glycoprotein-1.CCP3Citrullinated peptide third generation.COVID-19Coronavirus disease 2019.CRPC reactive protein.dsDNADouble-stranded DNA.ELISAEnzyme-linked-immunosorbent assay.ICUIntensive care unit.IQRInterquartile range.PCAPrincipal component analysis.PCSPost-COVID syndrome.RFRheumatoid Factor.RNPRibonucleoprotein.SARS-CoV-2Severe acute respiratory syndrome coronavirus 2.SmSmith.TgThyroglobulin.TPOThyroid peroxidase.